Скачать или смотреть Outcomes of CD19-directed CAR T-cell therapy in five individuals with multiple sclerosis

Johanna Richter, Transplant Physician, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, comments on the preliminary data from her center's experience with a CD19-directed CAR T-cell therapy in five patients with multiple sclerosis (MS). The data indicates mild cytokine release syndrome (CRS) and no immune effector cell-associated neurotoxicity syndrome (ICANS), typical side effects of CAR-T therapies, and expansion-dependent effects on oligoclonal bands. Dr Richter notes that these findings support the safety of CAR T-cell therapy in MS and warrant further study. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.